FLT3 and acute myeloid leukemia: Favorable OS in the transplanted patients could also be attributed to our transplant approach favoring myeloablative conditioning for better disease control in all fit patients of appropriate age [41], using CLARA/BRIDGE sequential therapy in patients with resistant disease and sorafenib in patients with FLT3-ITD-positive AML for post-transplant maintenance therapy [42].